Recently some other RA biomarkers of the same protein family, ACPA (anti-citrullinated protein antibodies) have been introduced on the market. The diagnostic value of CCPlus® in comparison with two of them; CCP3.1 and MCV, was investigated in an in-house study. Our results were compared to data presented in peer reviewed publications and confirm the position of anti-CCP2 as the ACPA test of highest diagnostic value.
The study was presented during the 11th Dresden Symposium on Autoantibodies, September 2, 2013. You find the link to the poster here.
A literature survey summarising the role of anti-CCP2 in RA diagnosis is provided here.
1. Pruijn et al. Arthritis Research & Therapy 2010, 12:203« Back